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One of the major problems in genomics and medicine is the identiﬁcation of gene networks and pathways
deregulated in complex and polygenic diseases, like cancer. In this paper, we address the problem of
assessing the variability of results of pathways analysis identiﬁed in different and independent genome
wide expression studies, in which the same phenotypic conditions are assayed. To this end, we assessed
the deregulation of 1891 curated gene sets in four independent gene expression data sets of subjects
affected by colorectal cancer (CRC). In this comparison we used two well-founded statistical models
for evaluating deregulation of gene networks. We found that the results of pathway analysis in expres-
sion studies are highly reproducible. Our study revealed 53 pathways identiﬁed by the two methods in
all the four data sets analyzed with high statistical signiﬁcance and strong biological relevance with
the pathology examined. This set of pathways associated to single markers as well as to whole biological
processes altered constitutes a signature of the disease which sheds light on the genetics bases of CRC.
 2009 Elsevier Inc. All rights reserved.1. Introduction
Identifying individual genes and gene networks involved in on-
set and progression of complex and polygenic diseases is a major
challenge of the current research in medicine and, in particular,
in oncology [1,2]. The modern DNA microarray technologies play
a fundamental role in the achievement of this ambitious objective
as they allow to obtain quantitative, genome-wide descriptions of
the expression levels of genes in tissues under different phenotypic
conditions [3].
Although the great potential offered by these technologies,
there is a unanimous consensus to judge with caution the results
obtained by DNA microarray experiments because they are poorly
reproducible. In fact, when we compare results obtained by differ-
ent microarray studies which examine the same biological condi-
tions, e.g. differential expression between tumor and normal
samples, the lists of differentially expressed (DE) genes show little
overlap [4,5]. Moreover, dissimilar lists of DE genes also result
when different statistical approaches are used for analyzing the
data [6]. In [4], for example, the authors analyzed three public data
sets, consisting of normal and tumor samples of prostate, by usingll rights reserved.
.two distinct statistical methods: Statistical Analysis of Microarray
(SAM) [7] and Mixed Model Analysis (MMA) [8]. Both methods
produced lists of DE genes having only the 6% of DE genes common
in the three data sets. Moreover, the overlap reduced to 3% consid-
ering the common DE genes identiﬁed by the two methods.
The reasons of this lack of reproducibility stem from (a) the uni-
variate statistics adopted which do not take into account gene
interactions and (b) the need of limiting the effects of multiple
hypothesis testing.
To overcome these shortcomings which make results by micro-
array experiments difﬁcult to compare, a new trend has emerged
recently in computational biology in which the activity of a gene
or of a whole biological process in a disease is assessed by using
sets of genes [9–13]. These gene sets code biological pathways,
such as cellular functions and biological processes, or represent a
unique signature of deregulation of a given gene [14]. The former
are manually, knowledge-driven built gene sets in which anno-
tated genes are grouped on the basis of evidences coming from
knowledge bases and literature. The latter are experimentally de-
rived by analyzing the cell response to a given variation. In [11],
for example, the pathway or signature associated to the activity
of a given oncogene is deﬁned as the set composed of those genes
that most differentially express under the perturbation (impulse)
of the oncogene. So, for evaluating the activity of a given gene in
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ment of its signature in the given experimental conditions. This ap-
proach is analogous to procedures developed in the general
framework of system theory in which the properties of a given sys-
tem are studied characterizing the response of the system to the
impulse [15]. Under this perspective the problem of measuring
gene deregulation is an inverse problem because we want to detect
an event measuring its effects. Inverse problems are in general ill
posed and in this particular case the size of the signature acts as
regularization parameter [16].
In this paper, we address the problem of assessing the repro-
ducibility of results of pathway analysis obtained by microarray
experiments. In particular, we assess whether lists of pathways
found associated to given phenotypic conditions, determined in
independent microarray experiments, share biologically relevant
and statistically signiﬁcant pathways. To this end, we analyzed
data sets relative to four independent genome-wide expression
studies of colorectal cancer which compared normal versus tumor
tissues. Three data sets come from literature [17–19] and the
fourth is a new data set collected in Casa Sollievo della Sofferenza
Hospital, Foggia, Italy. In our analysis we used Molecular Signa-
tures Database (MSigDB) [9], a vast collection composed of 1891
curated gene sets collected from various sources such as online
pathway databases, publications in PubMed, and knowledge of do-
main experts. Moreover, to evaluate how the adopted statistical
model inﬂuences the reproducibility of the results, we applied
two well-known and statistically well-founded approaches which
assess pathway enrichment in expression studies: Gene Set Enrich-
ment Analysis (GSEA) [9] and Random-Set Methods (RS) [20].
Although these approaches aim at evaluating the association of
pathways with phenotypes they are deeply different. Moreover,
they use different strategies for assessing the statistical signiﬁ-
cance of the deregulation of pathways in the experimental condi-
tions analyzed.
Our study shows that pathway based approaches are suitable
for dissecting complex and polygenic diseases and provide signiﬁ-
cant and highly reproducible results. In particular, our analysis
highlights a signature of colorectal cancer composed of 53 statisti-
cally signiﬁcant and biologically relevant pathways found deregu-
lated in all the four data sets by both methods. The biological
relevance of this set of pathways in the pathology is analyzed in
depth. Finally, we provide a set of suggestions to users of gene
set methods.
2. Materials and methods
2.1. Data set description
Four microarray gene expression data sets of tumor vs normal
human colon tissues were analyzed in our study. The ﬁrst data
set (SGR1) is composed of 22 normal and 25 tumor specimens, pro-
ﬁled by using the Affymetrix HGU133A GeneChip (22283 probe-
sets) [17]. The microarray data are accessible through ArrayExpress
site, with Accession No. E-MTAB-57. The second data set (JIANG) is
composed of 24 pairs of normal and tumor colon specimens pro-
ﬁled by using Illumina BeadChip Human Ref8-v2 (22184 probe-
sets) [19]. The data can be downloaded by Gene Expression Omni-
bus with Accession No. GSE10950. The third data set (GARD) is
composed of 20 paired tumor-normal colon samples, proﬁled by
using the Affymetrix GeneChip Human Exon Array 1.0 ST (22011
genes) [18]. Finally, we analyzed a new data set (SGR2) collected
in Casa Sollievo della Sofferenza Hospital, Foggia, Italy, composed
of 14 paired tumor-normal samples, proﬁled by using the Affyme-
trix GeneChip Human Exon 1.0 ST (22011 genes). The data sets
were normalized by using the Robust Multi-array Average (RMA)
procedure [22,40].2.2. Gene sets
The database of gene sets used in this work was the C2 collec-
tion of the Molecular Signatures Database (MSigDB) [9]. This col-
lection consists of 1891 curated gene sets collected from various
sources such as online pathway databases, publications in PubMed,
and knowledge of domain experts.
2.3. Algorithms
We are given a data set S ¼ fðx1; y1Þ; ðx2; y2Þ; . . . ; ðx‘; y‘Þg com-
posed of ‘ labeled specimens, where xi 2 Rd, yi 2 f1;1g for
i ¼ 1;2; . . . ; ‘ and d is the number of probes on the microarray in
the adopted technology. Let us suppose we have ‘þ positive and
‘ negative examples, such that ‘ ¼ ‘þ þ ‘. Moreover, we are given
a gene set G ¼ fg1; g2; . . . ; gmg composed of m probes, where
m  d.
2.3.1. RS
Let si, i ¼ 1; . . . ; d, be a score associated to each probe. This score
is a quantitative measure of differential expression which in our
case is based on a two sample t-statistic for each gene ti, the two
samples are the two phenotypes or conditions. Speciﬁcally,
si ¼ U1ðbFðtiÞÞ, i ¼ 1; . . . ; d, where ti were the two-sample t-statis-
tics values computed for each gene, bFðtiÞ ¼ rankðtiÞ=d where
rankðtiÞ is the rank of the value ti in the array ½t1; . . . ; td, and U is
the standard normal cumulative distribution function. Given these
scores the measure of gene set deregulation is Z ¼ ðX  lÞ=r,
where X is the average of gene scores, X ¼ 1m
P
g2Gsg , and
l ¼ EfXg and r ¼ varfXg are easily computed from the full set of
gene scores. Large positive or negative values of Z are expected if
G is up-regulated or down-regulated in the experimental condi-
tions analyzed. P-values are computed using a non-parametric per-
mutation test [23] with 1000 permutations of the phenotypic
labels and false discovery rate (FDR) computations are provided
using the method described in [24].
2.3.2. GSEA
This method uses a variation of a Kolmogorov–Smirnov statistic
to provide an enrichment score for each gene set [9]. As in the ran-
dom set method a score measuring the correlation of a probe with
the phenotype is required, si, i ¼ 1; . . . ; d. We use the signal-to-
noise metric in the standard GSEA setting as our score. This metric
is very similar to the two sample t-statistic used in our implemen-
tation of RS. Based on these correlation scores and the adjusted
Kolmogorov–Smirnov statistic we compute an enrichment score
which is signed. Negative scores correspond to down-regulation
of the gene set and positive scores correspond to up-regulation
of the gene set. These enrichment scores are then normalized to
take into account the size of the gene sets resulting in a normalized
enrichment score. This normalization is done based on phenotypic
permutations followed by standardization, see [9]. P-values as well
as false discovery rates are computed using the standard setting of
the software.3. Results
We evaluated the deregulation of all the gene sets belonging to
MSigDB in the four microarray gene expression data sets indepen-
dently. In particular, for having more precise insights into the cel-
lular mechanisms involved in the pathology at hand, we assessed
up-regulated and down-regulated gene sets separately. With the
term up(down)-regulated pathway we mean a gene set enriched
of genes up(down)-regulated with respect to a given phenotypic
condition. Up- and down-regulation was always referred to tumor
Table 2
Percentage of false positive pathways identiﬁed by the two methods in the four data
sets.
GSEA RS
UP (%) DOWN (%) UP (%) DOWN (%)
SGR1 78 99 69 99
SGR2 65 98 68 98
JIANG 85 99 73 99
GARD 76 96 77 98
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a ¼ 0:05. Table 1 reports the number of up/down-regulated path-
ways identiﬁed by the two methods in each data set and the esti-
mated FDR. For example, in SGR1 data set, GSEA identiﬁed 240 up-
and 203 down-regulated gene sets with P 6 0:05 and FDR = 32% in
both cases. In the same data set, RS identiﬁed 166 up- and 112
down-regulated gene sets with P 6 0:05 and FDR = 31%. The num-
ber of common gene sets identiﬁed by both methods was 155 (up)
and 94 (down) as reported in the last two columns of Table 1. The
number of common gene sets identiﬁed by the two methods was
statistically signiﬁcant as assessed by using the Fisher’s exact test.
A complete description of the results obtained by the two methods
on the four data sets is given as supplemental material.
As Table 1 shows, the up-regulation signals are stronger than
the down-regulation ones, consistently in all the data sets ana-
lyzed. In fact, the range of up-regulated pathways is [148, 356]
and [164, 228] as identiﬁed by GSEA and RS, respectively. The
range of down-regulated pathways, on the contrary, is [23, 298]
for GSEA and [57, 137] for RS, and in two data sets (SGR2 and
GARD) the number of down-regulated gene sets is smaller than
the expected number of pathways deregulated by chance. In fact,
in the case of independency between gene expression levels and
phenotype, we expect to ﬁnd na ¼ 95 pathways deregulated at
0.05 level by chance, where n ¼ 1891 is the number of assessed
gene sets.
This consideration is conﬁrmed by analyzing (a) the number of
pathways up- and down-regulated identiﬁed simultaneously by
the two methods in each data set (the last two columns of Table
1) and (b) the number the pathways which are consistently and
signiﬁcantly up- or down-regulated in all the data sets (the last
row of Table 1). In fact, the number of gene sets identiﬁed simulta-
neously by the two methods ranges in [98, 189] (up) and [19, 129]
(down). Moreover, the number of pathways up-regulated in all the
data sets with P 6 0:05 is 73 identiﬁed by GSEA and 87 identiﬁed
by RS. Both methods identiﬁed only ﬁve gene sets down-regulated
in all the data sets with P 6 0:05.
Intersecting the lists of gene sets identiﬁed independently by
the two methods, with P 6 0:05, in all the data sets analyzed, we
determined 52 up- and 1 down-regulated pathways. In Tables 5
and 6 we show the name of the 53 gene sets identiﬁed by both
methods together with the statistical parameters relative to each
gene set as evaluated by GSEA and RS, respectively. The last col-
umn reports the median rank of the pathway in the four data sets.
This list of 53 gene sets constitute a signature of the pathology in
terms of pathways deregulated and we use it as gold standard
for our successive statistical assessments. In supplemental materi-
als, we report the statistical parameters relative to this set of path-
ways as estimated by the two methods on the four data sets.
Moreover, we provide a detailed analysis concerning the biological
and functional relevance of these pathways in colorectal cancer at
the end of this section.
After having deﬁned the gold standard, i.e. the pool of pathways
signiﬁcantly altered in the phenotypic conditions examined, it is
interesting to estimate the rate of false positive (FP) pathwaysTable 1
Number of up- and down-regulated pathways identiﬁed by the two methods with P 6 0:0
GSEA RS
UP FDR (%) DOWN FDR (%) UP
SGR1 240 32 203 32 166
SGR2 148 100 46 100 164
JIANG 356 23 298 32 190
GARD 217 81 23 89 228
Overlap 73 5 87identiﬁed in an experiment as a function of (a) the statistical meth-
od adopted for assessing deregulation and (b) the available data. In
Table 2, we report the FP rate evaluated comparing the set of path-
ways associated to the phenotype with P 6 0:05 and the gold stan-
dard. Although RS performs slightly better than GSEA in terms of
FP pathways, the rate of FP gene sets identiﬁed as deregulated by
analyzing one data set only is extremely high. A possible strategy
for reducing the FP rate is intersecting lists of deregulated path-
ways identiﬁed by using different data sets. In Table 3, we report
the number of pathways simultaneously deregulated in two data
sets and the corresponding FP rate. The rate of FP up-regulated
pathways reduces to a median value of 57% for both methods
and this value reduces to 46% if we intersect lists obtained by ana-
lyzing three different data sets (see Table 4).
The last consideration concerns the methods adopted for
assessing deregulation. Although their statistical bases are deeply
different, our analysis shows that they perform similarly in all
the experimental conditions analyzed. In particular the lists of
pathways associated to the phenotype produced by the two meth-
ods show a signiﬁcant overlap. We measured the intersection of
the two rank-ordered gene set lists produced by GSEA and RS as
a function of the number of considered gene sets (see Fig. 1). As
the picture shows, intersecting the lists composed of the mostly
deregulated 150 gene sets produced by each method, the overlap
range from 62% to 77% in the four data sets.4. Biological discussion
We analyzed in depth the biological relevance of the 53 path-
ways identiﬁed as deregulated in the four data sets by the two
methods, listed in Table 5 or 6. We reported a brief description
of the single pathways belonging to this group, which could be
used as diagnostic biomarkers, and underlined their importance
in oncogenesis. Most gene sets have been already shown to be in-
volved in colorectal tumorigenesis. Some of these pathways are re-
lated to cell cycle, whose deregulation has been identiﬁed as one of
the hallmarks of cancer [32]. Numerous genes that change expres-
sion during colon cancer progression encode proteins related to
cell cycle and proteins involved in growth and differentiation
[28]. The human cell cycle in normal somatic cells is characterized
by its high precision. This remarkable accuracy is achieved by a
number of signal transduction pathways, known as checkpoints,5 and the corresponding FDR.
Overlap
FDR (%) DOWN FDR (%) UP DOWN
31 112 31 155 94
39 57 39 98 23
27 137 27 189 129
29 61 29 155 19
5 52 1
Table 3
Number of pathways identiﬁed by (a) GSEA and (b) RS in two data sets
simultaneously. The FP rate is reported in parentheses. The upper and lower
triangular parts of the tables contain the number up- and down-regulated pathways,
respectively.
SGR1 SGR2 JIANG GARD
(a)
SGR1  103 (50%) 204 (75%) 128 (59%)
SGR2 29 (97%)  112 (54%) 94 (45%)
JIANG 102 (99%) 25 (96%)  170 (69%)
GARD 14 (93%) 9 (89%) 11 (91%) 
(b)
SGR1  103 (50%) 128 (59%) 120 (57%)
SGR2 25 (96%)  114 (54%) 123 (58%)
JIANG 54 (98%) 20 (95%)  150 (65%)
GARD 21 (95%) 16 (94%) 16 (94%) 
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Fig. 1. Overlap of the lists of deregulated gene sets produced by GSEA and RS in the
four data sets. The x-axis represents the size of the list and the y-axis represents the
overlap in each pairwise comparison.
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of S-phase and mitosis, the integrity of the genome and the ﬁdelity
of chromosome segregation. Cell cycle checkpoints are essential in
eukaryotes for ensuring high ﬁdelity transmission of genetic infor-
mation from one generation to the next. They include DNA damage
checkpoints, DNA replication checkpoints, spindle assembly check-
points, and cytokinesis checkpoints. The ﬁrst gene set analyzed
was ARFPATHWAY belonging to Biocarta database. This pathway
was related to cell cycle because it includes genes, such as
CDKN2A, that have the ability to elicit a p53 response and a dis-
tinctive cell cycle arrest in both the G1 and G2/M phases, acting
as tumor suppressors. Other gene sets of the cell cycle found dereg-
ulated in our colon cancer data sets, are BRENTANI CELL CYCLE that
contains cancer related genes involved in the cell cycle [29], CELL
CYCLE belonging to Gene Ontology data base, CELL CYCLE KEGG,
HSA04110 CELL CYCLE [41] and GOLDRATH CELLCYCLE [34] that
includes cell cycle genes induced during antigen activation of
CD8+ T cells. Moreover we found CELLCYCLEPATHWAY, belonging
to Biocarta data base, which analyzes the interplay of many mole-
cules that regulate the cell cycle, underlining the key role of the
cyclins which combine with cyclin dependent kinases to drive
the stages of the cell cycle. A breakdown in the regulation of this
cycle can lead to out of growth control and contribute to tumor for-
mation. Defects in many of the molecules that regulate the cell cy-
cle have been implicated in cancer. P53, the cdk inhibitors (p15,
p16, p18, p19, p21, p27), and Rb are among key genes acting to
keep the cell cycle from progressing until all repairs to damaged
DNA have been completed. Indeed among our 52 deregulated path-
ways, we found P21 ANY DN and P21 EARLY DN pathways that
highlight the role of p21 in p53-independent apoptosis; instead
P21 P53 ANY DN, P21 P53 EARLY DN pathways consider p53-
dependent p21-induced apoptosis [62] and P27PATHWAY, a Bio-
carta data base pathway, blocks cell cycle progression through
the G1–S transition. Low levels of p27 protein were found associ-
ated with high aggressiveness and poor prognosis among patientsTable 4
Number of pathways identiﬁed by GSEA and RS in three data sets simultaneously. The FP
SGR1, SGR2, JIANG
GSEA RS
UP DOWN UP DOWN
97 (46%) 17 (94%) 94 (45%) 13 (92%)
SGR1, JIANG, GARD
GSEA RS
UP DOWN UP DOWN
120 (57%) 9 (89%) 110 (53%) 12 (92%)with a variety of malignancies, including colorectal carcinoma [55].
These studies suggested that the decline in p27 levels may contrib-
ute to uncontrolled proliferation of malignant cells, because p27 is
a negative regulator of the protein kinases Cdk2/cyclin E and Cdk2/
cyclin A, which drive cells into the S phase of the cell division cycle
[53]. The loss of p27 in patients with malignant disease results
from increased protein degradation. The machinery involved in
targeting p27 for degradation is an SCF type ubiquitin ligase com-
plex that contains S phase kinase protein 2 (Skp2) as the speciﬁc
substrate recognizing the subunit. Recent studies show that Skp2
is overexpressed and inversely related to p27 in colorectal carci-
noma. Increased protein and gene expression of Skp2 were found
to be strongly correlated with high tumor aggressiveness, suggest-
ing that Skp2 acts as an oncogene by promoting the rate of p27
degradation [38]. Skp2 protein recruits also E2F for ubiquitination
and degradation; E2F-1 is a transcription factor that regulates the
expression of genes involved in the cell cycle and that is involved
in progression of the cell cycle from G1 into S phase. Over-expres-
sion of E2F-1 can induce cellular transformation and its under-
expression can repress apoptosis. Knowledge of E2F-1 activity
and its regulation represents only a part of the complex set of
interactions regulating the cell cycle and potential targets for the
treatment of cancer. In our analysis we found SKP2E2FPATHWAY,
belonging to Biocarta data base, that analyzes the transcription fac-
tor E2F-1 and the expression of transcriptionally regulated genes
required for S-phase entry and DNA synthesis. Some ﬁndings sug-rate is reported in parentheses.
SGR1, SGR2, GARD
GSEA RS
UP DOWN UP DOWN
76 (32%) 8 (88%) 90 (42%) 11 (91%)
SGR2, JIANG, GARD
GSEA RS
UP DOWN UP DOWN
84 (38%) 6 (83%) 100 (48%) 6 (83%)
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eration in human colon cancer cells lines [59]. Another group of
cell cycle pathways found deregulated in our analysis regards the
interphase and its checkpoints that are used by the cell to monitor
and regulate the progress of the cell cycle. G1PATHWAY, belonging
to Biocarta data base, analyses the G1/S cell cycle checkpoint that
controls the passage of eukaryotic cells from the ﬁrst gap phase
(G1) into the DNA synthesis phase (S). Two cell cycle kinases,
CDK4/6–cyclin D and CDK2–cyclin E, and the transcription com-
plex that includes Rb and E2F are pivotal in controlling this check-
point. During G1 phase, the Rb-HDAC repressor complex binds to
the E2F–DP1 transcription factors, inhibiting the downstream tran-
scription. Phosphorylation of Rb by CDK4/6 and CDK2 dissociates
the Rb-repressor complex, permitting transcription of S-phase
genes encoding for proteins that amplify the G1 to S phase switch
and that are required for DNA replication. Many different stimuli
exert checkpoint control including TGFb, DNA damage, contact
inhibition and growth factor withdrawal. G1 TO S CELL CYCLE
REACTOME analyses the G1/S transition. In this phase the Cyclin
E–Cdk2 complexes control the transition from G1 into S-phase. Fi-
nally we found G2PATHWAY, also belonging to Biocarta data base,
which deals with the G2/M DNA damage checkpoint preventing
the cell from entering mitosis (M phase) if the genome is damaged.
The Cdc2–cyclin B kinase is pivotal in regulating this transition.
Another pathway related to cell cycle was CIS XPC UP [60]. XPC
is an important DNA damage recognition protein involved in
DNA nucleotide excision repair. Experimental studies about the
role of the XPC protein in cisplatin treatment-mediated cell cycle
regulation, have shown that the cell cycle and cell proliferation-re-
lated genes were the most affected by the XPC defect in the cis-
platin treatment. Many other cellular function genes were also
affected by the XPC defect in the treatment; the XPC defect reduced
the p53 responses to the cisplatin treatment and the ability to acti-
vate caspase-3 was also attenuated. These results suggest that the
XPC protein plays a critical role in initiating the cisplatin DNA dam-
aging treatment-mediated signal transduction process, resulting in
activation of the p53 pathway and cell cycle arrest that allow DNA
repair and apoptosis to take place. These results reveal an impor-
tant role of the XPC protein in the cancer prevention. Also the anal-
ysis of SERUM FIBROBLAST CELLCYCLE [31] and UNDERHILL
PROLIFERATION [56] showed cell cycle- and proliferation-related
genes. The transcriptional signature of all these pathways could
provide a powerful predictor of the clinical course in several com-
mon carcinomas, such as in colorectal cancer, predicting increased
risk of metastasis and death. Besides cell cycle pathways, we found
another 22 pathways overexpressed in cancer tissues and that
might be good markers for prognosis of colorectal cancer. Among
these we found HDACI COLON BUT12HRS DN and HDACI COLON
BUT24HRS DN [44] that are two pathways obtained experimen-
tally by SW260 colon carcinoma cells when they are downregu-
lated by butyrate. The short-chain fatty acid butyrate is a
physiological regulator of many pathways of colonic epithelial cell
maturation, cell cycle arrest, lineage-speciﬁc differentiation and
apoptosis. Thus microarray analysis of gene expression proﬁles
can be used to characterize and distinguish the mechanisms of re-
sponse of colonic epithelial cells to physiological and pharmacolog-
ical inducers of cell maturation. This has important implications for
characterization of chemopreventive agents and recognition of po-
tential toxicity. Another two important pathways were HSA00790
FOLATE BIOSYNTHESIS and ONE CARBON POOL BY FOLATE [41]
that include genes involved in folate biosynthesis. Considerable
epidemiologic evidence suggests that a low-folate diet is associ-
ated with an increased risk of colorectal cancer, although the
results of a recent randomized trial indicate that folate supplemen-
tation may not reduce the risk of adenoma recurrence. In labora-
tory models, folate deﬁciency appears to induce p53 mutation[49]. Furthermore we found MYC ONCOGENIC SIGNATURE [27]
and SCHUMACHERMYC UP [50] pathways that consider Myc onco-
gene, the genes up-regulated by Myc and its role in cell cycle pro-
gression, apoptosis and cellular transformation. Mutations,
overexpression, rearrangement and translocation of this gene have
been associated with a variety of tumors. Myc protects from p53-
mediated apoptosis. Some ﬁndings indicated that failure of the
normal apoptotic process together with deregulation of Myc pro-
to-oncogene might promote the development of colorectal tumors
and its overexpression is observed in most colorectal cancers
[36,51]. MANALO HYPOXIA DN [43] gene set considered genes
downregulated under hypoxic conditions. Hypoxia refers to the
condition that a cell experiences under oxygen deﬁciency. Alterna-
tively, cancer cells can genetically elicit a hypoxic response in the
setting of normal oxygen levels to activate new blood vessel forma-
tion to experience a growth advantage. For example, VEGF gene,
which is generally up-regulated by hypoxic conditions, promotes
normal blood vessel formation and angiogenesis related to tumor
growth. Its expression is induced in colon and other cancer cells
as a result of hypoxia and multiple genetic alterations; probably
VEGF works as regulators of colon cancer cell invasion [37]. Two
important pathways for colorectal cancer prognosis were SANSOM
APC LOSS4 UP and SANSOM APC LOSS5 UP [48] that contain genes
upregulated following Apc loss. Apc is well characterized as a tu-
mor-suppressor gene in the intestine; although the function of
APC, speciﬁcally mutated in familial adenomatous polyposis
(FAP), is unknown, there is some evidence that it may affect apop-
tosis in colorectal epithelial cells. Mutations of APC gene are asso-
ciated with the earliest stages of colorectal tumorigenesis [46].
Then we found other two pathways, CROONQUIST IL6 RAS DN
and CROONQUIST IL6 STARVE UP [25], that show gene expression
patterns involved in the effects of IL-6 response and N-ras-activat-
ing mutations. IL-6 stimulates cell growth through Ras-mitogen-
activated protein kinase (MAPK) signaling pathway targets; it has
been shown to be a potent mitogen and survival factor for cancer
cells. In fact most upregulated genes of these gene set are involved
in cell cycle progression. Also Ras protein controls cell growth and
differentiation by transduction of extracellular mitogenic signals.
Furthermore Ras gene mutation is an important type of somatic
alteration identiﬁed in a variety of tumors including colorectal can-
cers; ras gene mutations may be the initiating event in colorectal
tumors; adenomas with ras gene mutations may be favorable to
progress [33]. DOX RESIST GASTRIC UP [42] pathway contained
genes upregulated in gastric cancer cell lines resistant to doxorubi-
cin, compared to parent chemosensitive lines. The differential
expression is associated with the acquisition of resistance in hu-
man gastric cancer cells. A major obstacle in chemotherapy is
treatment failure due to anticancer drug resistance. The emergence
of acquired resistance results from host factors and genetic or epi-
genetic changes in the cancer cells. The resistance itself may be due
to decreased drug accumulation, alteration of intracellular drug
distribution, reduced drug–target interaction, increased detoxiﬁca-
tion response, cell-cycle deregulation, increased damaged-DNA re-
pair and reduced apoptotic response. Many studies focus on a
limited number of candidate genes in chemoresistance which will
be used as novel chemotherapeutic targets for the treatment or
prevention of cancer; for example, it is well known that overex-
pression of the multidrug resistance gene (MDR1) is associated
with cancer cells that have drug resistance. Cell cycle deregulation
is an important molecular event in the acquisition of drug resis-
tance. Most of the genes identiﬁed overexpressed in doxorubicin-
resistant gastric cancer cells were involved in the cell cycle. Some
genes, as MDK gene, are frequently overexpressed not only in gas-
tric cancer, but also in a variety of tumors including colon cancer.
Another pathway analyzed was GAY YY1 DN [26] that include a list
of YY1 target genes. YY1 transcription factor coordinates multiple
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network. Some ﬁndings suggested that YY1 has an important role
in the control of cell growth, proliferation, apoptosis, oncogenic
transformation, and differentiation. HSA03020 RNA POLYMERASE
[41] pathway considers genes involved in RNA polymerase func-
tions. Transcription of rRNA and tRNA genes by RNA polymerases
I and III is essential for sustained protein synthesis and is therefore
a fundamental determinant of the capacity of a cell to grow. When
cell growth is not required, this transcription is repressed by reti-
noblastoma protein, p53 and ARF. This gene set is included in
our analysis because the inactivation of these tumor suppressors
in cancers deregulates RNA polymerases I and III, and oncopro-
teins, such as Myc, can stimulate these systems further. Such
events might have a signiﬁcant impact on the growth potential
of tumors [61]. In the comparison of 3T3-L1 ﬁbroblasts into adipo-
cytes with IDX (insulin, dexamethasone and isobutylxanthine) vs.
ﬁbroblasts treated with IDX + TSA (trichostatin A) to prevent dif-
ferentiation, IDX TSA UP CLUSTER3 pathway [30] consists of
strongly up-regulated genes. TSA is an inhibitor of histone deacet-
ylases (HDAC). HDACs are generally associated with gene repres-
sion. Compared to non-malignant cells, colon cancer cells exhibit
increased HDACs activity. HDAC1 and HDAC3 are upregulated in
colon cancer cells and in primary colon cancer; moreover silencing
of HDAC1 and HDAC3 in colon cancer cells induces apoptosis [54].
Then we analyzed INOS ALL UP [63] pathway that encloses several
modulated families of genes, including genes coding for proinﬂam-
matory transcription factors, cytokines, cytokine receptors, pro-
teins associated with cell proliferation and cellular energetics, as
well as proteins involved in apoptosis. In this study it was seen that
inducible nitric oxide synthase (iNOS) acts to suppress prolifera-
tion and protein synthesis and modulates several genes associated
with apoptosis, leading to a full anti-apoptotic effect. IRITANI AD-
PROX UP [39] pathway analysed the biological balance between
Myc and Mad gene levels that control expression of growth regu-
lating genes. MAD proteins antagonize the functions of MYC onco-
proteins, and the latter are deregulated in the majority of human
cancers. While MYC sensitizes cells to pro-apoptotic signals, the
transcriptional repressor MAD1 inhibits apoptosis in response to
a broad range of stimuli, including oncoproteins. PEART HISTONE
DN [45] gene set included genes related to cell proliferation down-
regulated by SAHA and depsipeptide, which are histone deacetyl-
ase inhibitors (HDACis). May be that, through the ability of
HDACis of regulating the expression of speciﬁc proliferative and/
or apoptotic genes, growth and survival of tumor cell are inhibited.
They regulate the expression of several genes within distinct apop-
tosis and cell cycle pathways. Then we analyzed SHEPARD GENES
COMMON BW CB MO [52] pathway which includes genes associ-
ated with cell cycle and cancer susceptibility. One gene identiﬁed
in this study is B-myb, which is part of a small family of transcrip-
tion factors with characteristic regions of homology that includes
the c-myb proto-oncogene. Some studies showed that B-myb plays
a role in cell cycle regulation, particularly at the G1/S transition,
and that loss of function of this gene is associated with cancer. An-
other two pathways found deregulated in our analysis were VANT-
VEER BREAST OUTCOME GOOD VS POOR DN [57] that consists of
genes regulating cell cycle, invasion, metastasis and angiogenesis,
and VERNELL PRB CLSTR1 [58] that contains pRB pathway target
genes. This last pathway included the genes found down-regulated
by pRB and p16 and up-regulated by E2F. Deregulation of the ret-
inoblastoma protein (pRB) pathway is a hallmark of human cancer
[32]. The core members of this pathway include the tumor sup-
pressor protein pRB which regulates progression through the cell
division cycle. The expression of pRB and p16 resulted in signiﬁ-
cant repression and activation of a large number of genes. Tran-
scriptional changes were found in genes that are essential for
DNA replication and cell proliferation. Then we found two path-ways, CANCER NEOPLASTIC META UP and CANCER UNDIFFERENTI-
ATED META UP [47], that included genes upregulated in cancer vs
normal tissues comparison in the ﬁrst pathway, and in undifferen-
tiated vs well-differentiated tumors comparison in the second gene
set. These two gene sets highlight a transcriptional proﬁle that is
commonly activated in various types of undifferentiated cancer:
this suggests common molecular mechanisms by which cancer
cells progress and avoid differentiation. Another two interesting
pathways found deregulated in our analysis were BRCA PROGNO-
SIS NEG [57] that contains genes whose expression is negatively
correlated with breast cancer outcomes and BREAST DUCTAL CAR-
CINOMA GENES that includes genes upregulated in breast tumors.
Likely we found these pathway because some ﬁndings suggested
an association between the risk of breast and colorectal cancers.
Some evidences highlight an important role for insulin and insu-
lin-like growth factors (IGFs) in the promotion of carcinogenesis
in both organs. Also BRCA1 gene that acts as a tumor suppressor,
in some studies was found deregulated in the two types of cancer.
In fact defects in BRCA1 are a cause of genetic susceptibility to
breast cancer and mutations in BRCA1 are thought to be responsi-
ble for 45% of inherited breast cancer; however BRCA1 mutation
carriers have a 4-fold increased risk of colon cancer. Loss of heter-
ozygosity at the BRCA1 gene locus was shown to be associated
with shorter survival in colorectal cancer; moreover recent evi-
dences showed that the expression of ATM and BRCA1 is a prog-
nostic marker in colorectal cancer [35]. The only down-regulated
pathway identiﬁed (1 AND 2 METHYLNAPHTHALENE DEGRADA-
TION) includes genes belonging to the alcohol dehydrogenase fam-
ily. Members of this enzyme family metabolize a wide variety of
substrates, including ethanol, retinol, other aliphatic alcohols,
hydroxysteroids, and lipid peroxidation products. The enzyme en-
coded by ADH7 gene is active as a retinol dehydrogenase; thus it
may participate in the synthesis of retinoic acid, a hormone impor-
tant for cellular differentiation.5. Discussion and conclusions
In this paper, we have addressed the problem of reproducibility
of results of pathway analysis in genome-wide expression studies.
In particular we have assessed if lists of pathways obtained in dif-
ferent experiments, in which the same phenotypic conditions were
assayed, shown a statistically signiﬁcant and biologically relevant
overlap. To this end, we have used MSigDB [9] a vast collections
of 1891 curated gene sets coding biological processes, cellular
functions and in general gene networks deﬁned experimentally
as well as on the basis of a-priori knowledge. The deregulation of
pathways was assessed through GSEA [9] and RS [20], two meth-
ods which implement different statistical schemes for measuring
association of groups of genes to the phenotype. Finally, we ana-
lyzed the results obtained by these two methods applied to three
different gene expression data sets [17–19] plus a new data set col-
lected in Casa Sollievo della Sofferenza Hospital, Foggia, Italy, rela-
tive to subjects affected by colorectal cancer (see Section 2).
The main conclusion we can draw on the basis of our extensive
statistical assessment is that the results of pathway analysis are
highly reproducible. We determined a set composed of 53 path-
ways, simultaneously altered in all the four data sets analyzed,
having strong biological implications with the pathology, which
provides a signature of colorectal cancer in terms of deregulated
gene networks. They were determined independently by GSEA
and RS, two deeply different methods which aim at evaluating
the association of pathways with phenotypes. The former uses a
simple phenotypic permutation for evaluating the signiﬁcance of
the enrichment of a signature. The latter couples the classic permu-
tation scheme to a novel restandardization procedure which aims
Table 5
Statistical signiﬁcance and FDR of the set of 53 deregulated pathways as evaluated by GSEA in the four data sets. The ﬁrst 52 pathways are up-regulated and the last is the only
down-regulated gene set.
Pathway JIANG GARD SGR1 SGR2 Rank
P FDR P FDR P FDR P FDR
SANSOM APC LOSS4 UP 0.0E+00 0.0% 7.5E03 50.2% 0.0E+00 4.9% 2.1E03 100.0% 8
BRCA PROGNOSIS NEG 0.0E+00 0.1% 2.0E03 27.1% 0.0E+00 2.1% 3.9E02 43.7% 11
HSA04110 CELL CYCLE 0.0E+00 0.1% 3.9E03 48.7% 0.0E+00 2.1% 0.0E+00 100.0% 14
CELL CYCLE 0.0E+00 0.1% 2.4E02 27.0% 0.0E+00 2.0% 4.1E03 52.4% 18
G1 TO S CELL CYCLE REACTOME 0.0E+00 0.1% 4.8E02 29.5% 0.0E+00 2.4% 1.2E02 62.4% 24
SANSOM APC LOSS5 UP 0.0E+00 0.1% 0.0E+00 36.7% 0.0E+00 2.2% 1.7E02 57.8% 29
BRENTANI CELL CYCLE 0.0E+00 0.1% 1.8E02 35.0% 0.0E+00 2.3% 8.0E03 52.5% 29
CELL CYCLE KEGG 0.0E+00 0.1% 1.8E02 26.4% 0.0E+00 2.2% 1.0E02 57.4% 32
LI FETAL VS WT KIDNEY DN 0.0E+00 0.1% 9.9E03 26.3% 0.0E+00 2.0% 1.6E02 53.7% 32
GOLDRATH CELL CYCLE 0.0E+00 0.1% 3.9E03 34.9% 0.0E+00 3.0% 1.6E02 40.8% 38
BROWN MYELOID PROLIF AND SELF RENEWAL 0.0E+00 0.1% 0.0E+00 28.6% 2.0E03 2.8% 1.8E02 57.9% 40
CANCER NEOPLASTIC META UP 0.0E+00 0.2% 6.0E03 37.9% 1.9E03 2.4% 2.0E03 59.9% 42
UNDERHILL PROLIFERATION 0.0E+00 0.1% 9.8E03 24.2% 0.0E+00 2.2% 2.4E02 39.9% 44
CELLCYCLEPATHWAY 0.0E+00 0.1% 1.6E02 34.2% 0.0E+00 2.4% 2.3E02 51.6% 50
VANTVEER BREAST OUTCOME GOOD VS POOR
DN
0.0E+00 0.2% 7.9E03 24.6% 0.0E+00 3.3% 2.9E02 45.4% 51
GAY YY1 DN 0.0E+00 0.1% 1.2E02 27.0% 0.0E+00 2.3% 4.8E02 39.6% 53
HDACI COLON BUT12HRS DN 2.1E03 0.4% 6.1E03 25.7% 2.0E03 3.5% 1.4E02 62.2% 54
HDACI COLON BUT24HRS DN 6.1E03 1.4% 8.1E03 27.4% 2.0E03 5.7% 1.0E02 52.3% 55
ADIP DIFF CLUSTER5 0.0E+00 0.4% 4.3E02 26.8% 0.0E+00 2.4% 6.2E03 50.5% 56
IRITANI ADPROX UP 0.0E+00 0.1% 1.2E02 27.5% 0.0E+00 4.4% 2.3E02 53.5% 56
P21 ANY DN 0.0E+00 0.1% 1.3E02 24.0% 2.0E03 6.2% 6.0E03 52.5% 56
SHEPARD GENES COMMON BW CB MO 0.0E+00 0.0% 9.7E03 81.0% 2.0E03 2.5% 2.1E02 68.8% 60
CANCER UNDIFFERENTIATED META UP 0.0E+00 0.4% 3.9E03 43.9% 8.0E03 6.4% 2.2E02 46.9% 63
ADIP DIFF CLUSTER4 0.0E+00 0.3% 2.7E02 27.3% 1.9E03 4.6% 2.6E02 46.6% 66
LEE TCELLS3 UP 0.0E+00 0.1% 8.0E03 46.7% 4.1E03 3.1% 3.0E02 51.6% 70
SERUM FIBROBLAST CELLCYCLE 0.0E+00 0.1% 1.2E02 26.2% 2.0E03 2.4% 2.6E02 41.8% 71
PEART HISTONE DN 0.0E+00 0.1% 0.0E+00 27.2% 4.1E03 3.2% 4.6E02 50.7% 72
MYC ONCOGENIC SIGNATURE 0.0E+00 0.4% 2.9E02 27.2% 2.0E03 3.0% 2.3E02 100.0% 72
OLDAGE DN 0.0E+00 0.1% 2.6E02 27.0% 4.0E03 3.3% 2.0E02 39.8% 73
CIS XPC UP 0.0E+00 0.3% 2.0E02 27.9% 2.0E03 3.1% 2.8E02 50.2% 75
P21 P53 ANY DN 0.0E+00 0.2% 1.6E02 24.4% 2.0E03 3.1% 3.8E02 40.0% 79
INOS ALL UP 0.0E+00 0.4% 1.9E02 27.3% 3.9E03 3.0% 1.9E02 53.1% 81
ONE CARBON POOL BY FOLATE 0.0E+00 0.4% 4.5E02 28.1% 0.0E+00 2.1% 2.9E02 66.8% 81
SCHUMACHER MYC UP 0.0E+00 0.1% 2.3E02 29.0% 6.0E03 3.9% 1.9E02 53.2% 83
G1PATHWAY 2.0E03 0.5% 4.0E02 27.0% 0.0E+00 2.1% 6.3E03 60.7% 88
MANALO HYPOXIA DN 0.0E+00 0.2% 1.6E02 25.0% 3.9E03 2.4% 3.6E02 44.3% 88
CROONQUIST IL6 STARVE UP 2.0E03 1.2% 1.8E02 25.5% 0.0E+00 5.9% 2.6E02 40.0% 89
IDX TSA UP CLUSTER3 0.0E+00 0.1% 1.6E02 23.7% 4.0E03 3.1% 3.4E02 43.8% 89
ZHAN MM CD138 PR VS REST 0.0E+00 0.7% 0.0E+00 28.0% 8.0E03 6.6% 3.0E02 40.6% 90
SHIPP FL VS DLBCL DN 0.0E+00 0.1% 2.9E02 27.4% 1.2E02 4.3% 4.0E03 55.2% 93
VERNELL PRB CLSTR1 0.0E+00 0.1% 3.2E02 27.0% 4.0E03 4.6% 3.5E02 43.8% 97
G2PATHWAY 2.0E03 0.2% 4.9E02 26.8% 0.0E+00 2.0% 2.7E02 52.2% 110
CROONQUIST IL6 RAS DN 0.0E+00 1.1% 1.9E02 25.2% 6.0E03 7.7% 4.3E02 41.3% 111
P21 P53 EARLY DN 2.1E03 1.8% 1.4E02 28.3% 1.2E02 10.7% 1.2E02 39.3% 119
P27PATHWAY 4.1E03 1.6% 9.6E03 24.9% 1.4E02 7.2% 2.7E02 45.5% 121
ARFPATHWAY 2.0E03 1.8% 2.4E02 26.2% 6.0E03 6.0% 1.9E02 59.1% 123
HSA03020 RNA POLYMERASE 2.1E03 3.5% 5.0E02 27.1% 0.0E+00 2.2% 3.1E02 47.5% 126
P21 EARLY DN 0.0E+00 1.3% 3.7E02 26.9% 9.9E03 5.3% 0.0E+00 52.1% 127
DOX RESIST GASTRIC UP 0.0E+00 0.4% 3.9E02 27.7% 6.0E03 6.0% 4.9E02 41.0% 127
BREAST DUCTAL CARCINOMA GENES 2.1E03 1.1% 3.9E02 27.5% 4.0E03 4.3% 1.0E02 42.1% 128
HSA00790 FOLATE BIOSYNTHESIS 2.0E03 1.3% 3.6E02 27.3% 7.9E03 3.3% 2.1E03 100.0% 139
SKP2E2FPATHWAY 3.6E02 5.6% 2.0E02 27.0% 2.6E02 8.8% 3.2E02 41.2% 154
1 AND 2 METHYLNAPHTHALENE
DEGRADATION
2.9E02 17.0% 0.0E+00 59.7% 1.4E02 20.4% 3.8E02 62.5% 63
R. Maglietta et al. / Journal of Biomedical Informatics 43 (2010) 397–406 403at evaluating how the deregulation depends on the identity of the
genes present in the pathway. In particular, it aims at assessing if
lists of the same size composed of randomly selected genes from
the ones present on the microarray produce comparable enrich-
ments. In fact as admirably pointed out in [21] ‘‘any method for
assessing gene-sets should compare a given gene-set score not
only to scores from permutations of the sample labels, but also
has to take into account scores from sets formed by random selec-
tions of genes”.
Our study reveals that, although reproducible, the results of
pathway analysis have to be interpreted with caution when limited
to a single data set and, more importantly, suggests alternative andmore robust procedures of analysis of expression data. In fact, con-
sidering gene sets enriched in tumor samples only (see Table 2),
both methods have a FP rate in the range [65%, 85%]. This means
that more than half of the pathways identiﬁed as deregulated by
a method when applied to a single data set, are not conﬁrmed by
other studies analyzing the same phenotype. To reduce the FP rate
in the analysis of pathways we suggest an alternative approach
consisting in intersecting lists of deregulated pathways identiﬁed
in different data sets. In fact, as Table 3 shows, the FP rate de-
creases to [45%, 75%] and [50%, 65%] for GSEA and RS, respectively,
if we intersect lists of deregulated pathways identiﬁed in two dif-
ferent data sets. The FP rate reduces further in the ranges [32%,
Table 6
Statistical signiﬁcance and FDR of the set of 53 deregulated pathways as evaluated by RS in the four data sets. The ﬁrst 52 pathways are up-regulated and the last is the only
down-regulated gene set.
Pathway JIANG GARD SGR1 SGR2 Rank
P FDR P FDR P FDR P FDR
P21 P53 ANY DN 0.0E+00 0.0% 0.0E+00 0.0% 0.0E+00 0.0% 9.0E03 23.4% 8
OLDAGE DN 0.0E+00 0.0% 0.0E+00 0.0% 0.0E+00 0.0% 3.0E03 20.9% 13
ZHAN MM CD138 PR VS REST 0.0E+00 0.0% 0.0E+00 0.0% 1.0E03 3.5% 1.7E02 26.5% 13
CANCER NEOPLASTIC META UP 0.0E+00 0.0% 0.0E+00 0.0% 0.0E+00 0.0% 4.0E03 22.9% 14
CROONQUIST IL6 RAS DN 0.0E+00 0.0% 1.0E02 12.5% 0.0E+00 0.0% 6.0E03 23.4% 17
P21 P53 EARLY DN 0.0E+00 0.0% 0.0E+00 0.0% 1.0E03 3.5% 2.2E02 29.4% 17
CANCER UNDIFFERENTIATED META UP 0.0E+00 0.0% 1.0E03 3.6% 0.0E+00 0.0% 1.2E02 24.8% 20
LI FETAL VS WT KIDNEY DN 0.0E+00 0.0% 1.0E03 3.6% 0.0E+00 0.0% 1.0E03 12.8% 20
ADIP DIFF CLUSTER5 0.0E+00 0.0% 1.5E02 15.5% 0.0E+00 0.0% 6.0E03 23.4% 22
IDX TSA UP CLUSTER3 0.0E+00 0.0% 0.0E+00 0.0% 1.0E03 3.5% 1.6E02 25.7% 23
SERUM FIBROBLAST CELL CYCLE 0.0E+00 0.0% 0.0E+00 0.0% 1.0E03 3.5% 1.2E02 24.8% 23
BRCA PROGNOSIS NEG 2.0E03 4.2% 0.0E+00 0.0% 1.0E03 3.5% 3.0E03 20.9% 26
HSA04110 CELL CYCLE 0.0E+00 0.0% 0.0E+00 0.0% 0.0E+00 0.0% 1.4E02 25.0% 27
SANSOM APC LOSS4 UP 0.0E+00 0.0% 1.1E02 13.4% 0.0E+00 0.0% 1.0E03 12.8% 29
VANTVEER BREAST OUTCOME GOOD VS POOR DN 1.0E03 2.7% 2.0E03 5.4% 0.0E+00 0.0% 0.0E+00 0.0% 30
CELL CYCLE 0.0E+00 0.0% 1.0E03 3.6% 1.0E03 3.5% 1.0E02 24.2% 31
DOX RESIST GASTRIC UP 0.0E+00 0.0% 1.0E03 3.6% 2.0E03 5.6% 1.9E02 27.9% 32
CELL CYCLE KEGG 0.0E+00 0.0% 1.0E03 3.6% 1.0E03 3.5% 1.4E02 25.0% 34
LEE TCELLS3 UP 0.0E+00 0.0% 0.0E+00 0.0% 2.0E03 5.6% 2.1E02 28.7% 34
SHIPP FL VS DLBCL DN 1.0E03 2.7% 0.0E+00 0.0% 1.8E02 18.9% 3.0E03 20.9% 35
MANALO HYPOXIA DN 0.0E+00 0.0% 0.0E+00 0.0% 3.0E03 7.1% 2.1E02 28.7% 36
BRENTANI CELL CYCLE 0.0E+00 0.0% 1.0E03 3.6% 0.0E+00 0.0% 1.1E02 24.2% 37
UNDERHILL PROLIFERATION 0.0E+00 0.0% 4.0E03 7.7% 0.0E+00 0.0% 8.0E03 23.4% 37
GAY YY1 DN 6.0E03 8.2% 1.0E03 3.6% 0.0E+00 0.0% 6.0E03 23.4% 38
CROONQUIST IL6 STARVE UP 0.0E+00 0.0% 5.0E03 8.3% 1.0E03 3.5% 1.1E02 24.2% 40
P21 ANY DN 0.0E+00 0.0% 2.0E03 5.4% 5.0E03 9.8% 7.0E03 23.4% 41
GOLDRATH CELL CYCLE 0.0E+00 0.0% 1.0E03 3.6% 4.0E03 8.2% 1.1E02 24.2% 42
HDACI COLON BUT12HRS DN 0.0E+00 0.0% 1.0E03 3.6% 1.0E02 14.4% 8.0E03 23.4% 44
SANSOM APC LOSS5 UP 3.0E03 5.4% 0.0E+00 0.0% 9.0E03 13.6% 0.0E+00 0.0% 47
G2PATHWAY 0.0E+00 0.0% 3.0E03 6.5% 2.0E03 5.6% 1.4E02 25.0% 55
P21 EARLY DN 3.0E03 5.4% 1.7E02 16.4% 2.0E03 5.6% 2.0E03 17.0% 57
BROWN MYELOID PROLIF AND SELF RENEWAL 1.0E03 2.7% 3.0E03 6.5% 4.0E03 8.2% 6.0E03 23.4% 58
VERNELL PRB CLSTR1 0.0E+00 0.0% 1.0E03 3.6% 1.1E02 14.8% 2.3E02 29.6% 58
ADIP DIFF CLUSTER4 1.0E03 2.7% 5.0E03 8.3% 0.0E+00 0.0% 1.3E02 25.0% 59
HSA00790 FOLATE BIOSYNTHESIS 2.0E03 4.2% 2.0E03 5.4% 3.3E02 26.1% 2.0E03 17.0% 59
SCHUMACHER MYC UP 2.0E03 4.2% 3.0E03 6.5% 1.3E02 16.5% 9.0E03 23.4% 59
BREAST DUCTAL CARCINOMA GENES 0.0E+00 0.0% 4.0E03 7.7% 6.0E03 10.9% 1.1E02 24.2% 62
G1PATHWAY 4.0E03 6.5% 1.0E02 12.5% 0.0E+00 0.0% 7.0E03 23.4% 62
CIS XPC UP 1.0E03 2.7% 3.0E03 6.5% 7.0E03 11.7% 1.3E02 25.0% 70
G1 TO S CELL CYCLE REACTOME 0.0E+00 0.0% 8.0E03 11.3% 2.0E03 5.6% 4.5E02 37.9% 74
ARFPATHWAY 2.6E02 19.6% 3.0E03 6.5% 1.1E02 14.8% 8.0E03 23.4% 75
IRITANI ADPROX UP 3.0E03 5.4% 4.0E03 7.7% 1.2E02 15.5% 1.4E02 25.0% 77
HDACI COLON BUT24HRS DN 8.0E03 9.6% 2.0E03 5.4% 4.6E02 30.6% 5.0E03 23.1% 84
PEART HISTONE DN 4.0E03 6.5% 1.0E03 3.6% 1.5E02 17.6% 1.7E02 26.5% 87
SHEPARD GENES COMMON BW CB MO 0.0E+00 0.0% 2.8E02 21.2% 0.0E+00 0.0% 3.7E02 35.4% 90
MYC ONCOGENIC SIGNATURE 2.0E03 4.2% 1.7E02 16.4% 1.7E02 18.1% 3.0E03 20.9% 91
ONE CARBON POOL BY FOLATE 6.0E03 8.2% 7.0E03 10.6% 1.0E03 3.5% 3.3E02 33.3% 93
INOS ALL UP 7.0E03 8.9% 5.0E03 8.3% 1.9E02 19.5% 2.2E02 29.4% 102
CELLCYCLEPATHWAY 1.1E02 11.7% 1.5E02 15.5% 0.0E+00 0.0% 1.8E02 27.1% 106
SKP2E2FPATHWAY 2.1E02 17.1% 5.0E03 8.3% 3.5E02 27.1% 6.0E03 23.4% 111
HSA03020 RNA POLYMERASE 1.7E02 15.1% 5.0E03 8.3% 1.2E02 15.5% 4.4E02 37.6% 116
P27PATHWAY 1.8E02 15.7% 1.5E02 15.5% 4.2E02 29.4% 3.2E02 33.2% 138
1 AND 2 METHYLNAPHTHALENE DEGRADATION 1.5E02 14.0% 1.5E02 15.5% 1.0E03 3.5% 7.0E03 23.4% 15
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lists of pathways identiﬁed in three different data sets (see Table
4). Alternatively, when different data sets relative to the same phe-
notypic conditions are not available, our suggestion is to intersect
lists of deregulated pathways identiﬁed by different methods ap-
plied on the same data set.
The proposed approach of intersecting lists of pathways identi-
ﬁed in different data sets highlights an important aspect concerning
the usual estimators adopted for quantifying the statistical signiﬁ-
cance of discoveries. In statistical hypothesis testing, the P-value P
is the probability of obtaining a result at least as extreme as the one
that was actually observed, assuming that the null hypothesis is
true. This indicator is usually used in the case of single hypothesis
testing. In the case of multiple hypothesis testing, the simple P-va-lue is not useful anymore as indicator of the statistical signiﬁcance.
In fact, if we test n hypotheses in which the null hypothesis is true,
then by chance on average we will reject erroneously na null
hypotheses because P 6 a, with a as signiﬁcance level of the test.
In the case of multiple hypothesis testing a more suitable statistical
indicator is the false discovery rate (FDR) which takes into account
the number of hypotheses simultaneously tested. In fact it repre-
sents the rate of false discoveries among the s hypotheses accepted
as signiﬁcant: FDR ¼ na=s. So, if we accept s hypotheses as statisti-
cally signiﬁcant with an FDR of 25%, then it means that the 25% of s
are false discoveries. Also the FDR is not free of faults. In fact, the
FDR is not a good statistical indicator in those experimental condi-
tions, as the ones considered in this work, in which the ratio be-
tween the number of true alternative hypotheses (the size of the
R. Maglietta et al. / Journal of Biomedical Informatics 43 (2010) 397–406 405gold standard) and the number of hypothesis tested (the number of
pathways in MSigDB) is close to zero. At 0.05 level, the number of
pathways associated to the phenotype by chance (95) is larger than
the number of pathways really associated. In this experimental con-
ditions the signal is overwhelmed in the noise and it is difﬁcult to
separate the signal from the noise. As Tables 5 and 6 show, the
FDR is not a reliable indicator of the statistical signiﬁcance of path-
ways associated to the phenotype. In fact many pathways belong-
ing to the gold standard have FDR greater than the 30% in two
data sets and would have not been taken into account in successive
analysis. If a gene set has low P-value and high FDR in a single data
set, we cannot consider it as signiﬁcant. We can consider it as sig-
niﬁcant if the gene set receives low P-values in different data sets.
This is particularly important when the association between gene
set and phenotypical conditions is weak, that is when the involve-
ment of the pathway in the pathology is modest. The methodology
we propose is able to identify alsoweak association signals compar-
ing results obtained in different data sets.
Our genome-wide expression analysis of pathways altered in
subjects affected by colorectal cancer has highlighted numerous
markers well known to be associated to the pathology at hand. The
same approachmay be pursued for understanding the genetics basis
of other complex and polygenic diseases and for dissecting the
molecularmechanismsaltered inonsetandprogressionofneoplasia.
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